| Company Name: |
Alinda Chemical Ltd.
|
| Tel: |
+7 (495) 672-17-08 |
| Email: |
sale@alinda.ru |
| Products Intro: |
CAS:323176-64-3
Package:1mg Remarks:C15H11ClN2OS
|
| Company Name: |
Tianjin Kailiqi Biotechnology Co., Ltd.
|
| Tel: |
15076683720 |
| Email: |
klq@cw-bio.com |
| Products Intro: |
Product Name:WAY-303290
CAS:323176-64-3
Purity:≥98% Package:1g,5g,10g,25g根据客户需要分装 Remarks:Not For Human Use, Lab Use Only.
|
| Company Name: |
Jinan Jiuli Biotechnology Co. , Ltd.
|
| Tel: |
2717893647 14768611851 |
| Email: |
486064515@qq.com |
| Products Intro: |
Product Name:WAY-303290 ；GluR6 antagonist-1
CAS:323176-64-3
Purity:98% Package:500mg；1g；5g
|
|
| | 3-chloro-N-(pyridin-3-ylmethyl)-1-benzothiophene-2-carboxamide Basic information |
| Product Name: | 3-chloro-N-(pyridin-3-ylmethyl)-1-benzothiophene-2-carboxamide | | Synonyms: | 3-chloro-N-(pyridin-3-ylmethyl)-1-benzothiophene-2-carboxamide;Benzo[b]thiophene-2-carboxamide, 3-chloro-N-(3-pyridinylmethyl)-;WAY-303290;3-Chloro-N-(pyridin-3-ylmethyl)benzo[b]thiophene-2-carboxamide;Ionotropic glutamate receptors,Inhibitor,iGluR,WAY303290,benzothiophene derivative,chronic neurological disorders,inhibit,GluR6 antagonist-1,acute neurological disorders,WAY 303290;GluR6 antagonist-1 | | CAS: | 323176-64-3 | | MF: | C15H11ClN2OS | | MW: | 302.78 | | EINECS: | | | Product Categories: | | | Mol File: | 323176-64-3.mol |  |
| | 3-chloro-N-(pyridin-3-ylmethyl)-1-benzothiophene-2-carboxamide Chemical Properties |
| Boiling point | 543.5±50.0 °C(Predicted) | | density | 1.380±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 61 mg/mL (201.47 mM);Ethanol: 8 mg/mL (26.42 mM) | | pka | 11.98±0.46(Predicted) | | Water Solubility | Water: Insoluble |
| | 3-chloro-N-(pyridin-3-ylmethyl)-1-benzothiophene-2-carboxamide Usage And Synthesis |
| Biological Activity | WAY-303290 (GluR6 antagonist-1) is a benzothiophene derivative acting as an ionotropic glutamate receptor 6 (GluR6) antagonist, which can be used for researching acute and chronic neurological disorders. | | References | [1] BAKER STEPHEN RICHARD, et al. WO2001007431 A2 (example 20) |
| | 3-chloro-N-(pyridin-3-ylmethyl)-1-benzothiophene-2-carboxamide Preparation Products And Raw materials |
|